Skip to main content
. Author manuscript; available in PMC: 2022 May 22.
Published in final edited form as: Br J Pharmacol. 2021 Jun 11;178(18):3627–3647. doi: 10.1111/bph.15506

FIGURE 6.

FIGURE 6

BBIT20 inhibits the BRCA1-BARD1 interaction in triple-negative breast and ovarian cancer cells. (a–c) Co-IP was performed in MDA-MB-231 (a), HCC1937 (b) and IGROV-1 (d) cells treated with 12 and 20 μM BBIT20 for 18 h (in MDA-MB-231 and HCC1937 cells) and 24 h (in IGROV-1 cells). In (a)–(c), representative immunoblots are shown; whole-cell lysate is represented (input). In (d), quantification of BARD1 relative to DMSO (set as 1); BRCA1 from IP was used as loading control; data are mean ± SD, n = 5 independent experiments; *P <0.05 significantly different from DMSO (unpaired Student’s t-test)